Behavior of the combined use of plasma and Heberprot-P in diabetic ulcers, Guantánamo

Introduction: Diabetes Mellitus is one of the most common diseases. One of its most common complications is diabetic foot; this, in conjunction with other vascular alterations, can lead to amputation. The combined use of Heberprot-P and platelet-rich plasma provides another therapeutic alternative to facilitate healing.Objective: To determine the behavior of the combined use of platelet-rich plasma and Heberprot-P in diabetic ulcers in the Angiology Department of the "Dr. Agoustinho Neto" General Teaching Hospital, 2025.Method: A descriptive, retrospective, and longitudinal study was conducted. The sample consisted of (n = 50) patients discharged from the angiology department. Twenty-five patients with neuroinfectious diabetic foot and 25 with ischemic diabetic foot were randomly selected. The variables studied were: healing time, diabetic foot types, healing percentage, and Wagner grade.Results: 70% of patients achieved 75% ulcer healing, of which 42% were neuroinfectious diabetic foot ulcers. The most common Wagner grade was grade II, at 48%. Fifty-four percent of patients achieved maximum healing between days 8 and 14. No significant changes occurred during the first week after starting treatment.Conclusions: Neuroinfectious diabetic foot ulcers respond better to treatment with Heberprot P and Plasma. Wagner type II ulcers have a more satisfactory outcome than other ulcers. The use of these treatments reduces healing time by 2 weeks.